Pharvaris (PHVS) Net Income towards Common Stockholders Growth (1y) (2021 - 2026)
Powered by 
Analysis
Pharvaris (PHVS) Net Income towards Common Stockholders Growth (1y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 6.48% |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | -6.81% |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 92.37% |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 5.21% |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 151.28% |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 327.74% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | -12.04% |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 95.87% |
| 10 | Pharvaris | 2.14 Bn | 1.77 Bn | 85,072.10 | 5.97% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5.97% |
| Mar 31, 2026 | 6.35% |
| Dec 31, 2025 | -47.33% |
| Sep 30, 2025 | 5.42% |
| Jun 30, 2025 | 61.83% |
| Mar 31, 2025 | -60.79% |
| Dec 31, 2024 | -4.75% |
| Sep 30, 2024 | -78.72% |
| Jun 30, 2024 | -100.00% |
| Mar 31, 2024 | -24.98% |
| Dec 31, 2023 | 12.07% |
| Sep 30, 2023 | -207.77% |
| Jun 30, 2023 | 75.80% |
| Mar 31, 2023 | -35.30% |
| Dec 31, 2022 | -184.69% |
| Sep 30, 2022 | 22.58% |
| Jun 30, 2022 | 74,080,322.17% |
| Mar 31, 2022 | -146.69% |
| Dec 31, 2021 | -11.80% |
| Sep 30, 2021 | -44.23% |